Serum glutamine synthetase has no value as a diagnostic biomarker for Alzheimer's disease

Neurochem Res. 2011 Oct;36(10):1858-62. doi: 10.1007/s11064-011-0504-4. Epub 2011 May 20.

Abstract

In order to test whether serum glutamine synthetase (GS) is of potential diagnostic value for Alzheimer's disease (AD), we set up a study to compare serum GS concentrations between AD patients and control subjects. The study population (n = 165) consisted of AD patients (n = 94) and age-matched (n = 41) and age-unmatched (n = 30) control subjects. Serum GS analysis was performed by means of ELISA. No significant differences in serum GS levels were found between the AD group and age-matched controls. Age correlated positively with serum GS concentrations in AD patients and control subjects. This study suggests that serum GS levels have no diagnostic value for AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Alzheimer Disease / blood*
  • Alzheimer Disease / diagnosis*
  • Animals
  • Biomarkers / blood*
  • Female
  • Glutamate-Ammonia Ligase / blood*
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests

Substances

  • Biomarkers
  • Glutamate-Ammonia Ligase